<DOC>
	<DOC>NCT01585298</DOC>
	<brief_summary>Study to evaluate bradycardiac events during first dose observation of fingolimod in MS patients</brief_summary>
	<brief_title>STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Subjects with relapsing remitting MS with high disease activity despite treatment with a disease modifying therapy (&gt; 1 relapse in the previous year, &gt; 9 hyperintense T2 lesions or &gt; 1 Gdenhancing lesion or "nonresponding" which could be defined as unchanged or increased relapse rate or ongoing severe relapses compared to previous year) or patients with rapidly evolving severe RRMS (e.g. &gt; 2 relapses with disease progression in one year and &gt; 1 Gdenhancing lesion or with a significant increase in T2 lesions compared to a recent MRI). immunocompromised patients active infections pregnant or nursing women, women of childbearing potential unless using 2 reliable forms of contraception Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Gilenya</keyword>
	<keyword>ECG</keyword>
	<keyword>Bradyarrythmia</keyword>
	<keyword>conduction abnormalities</keyword>
	<keyword>first dose observation</keyword>
</DOC>